Towards sustained silencing of HER2/neu in cancer by epigenetic editing

Molecular Cancer Research

Volumn 11, Issue 9, 2013, Pages 1029-1039

  Falahi, Fahimeh ^a   Huisman, Christian ^a   Kazemier, Hinke G ^a   Van Der Vlies, Pieter ^a   Kok, Klaas ^a   Hospers, Geke A P ^a   Rots, Marianne G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE METHYLTRANSFERASE; LAPATINIB; ZINC FINGER PROTEIN;

ARTICLE; BINDING KINETICS; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GENETICS; CELL METABOLISM; CELL PROLIFERATION; CELL STRAIN HEK293; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENETIC ASSOCIATION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; NUCLEAR LOCALIZATION SIGNAL; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HEK293 CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MCF-7 CELLS; METHYLATION; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; TRANSCRIPTION FACTORS;

EID: 84884475055     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0567     Document Type: Article

References (48)

1. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009;21:177-84.
2. Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 2001;3:385-9. (Pubitemid 34196365)
3. Tapia C, Glatz K, Novotny H, Lugli A, Horcic M, Seemayer CA, et al. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol 2007;20:192-8. (Pubitemid 46422173)
4. Tapia C, Savic S, Wagner U, Schönegg R, Novotny H, Grilli B, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007;9:R31.
5. Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 2012;136:691-7.
6. Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B, et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol 2004;15:104-12. (Pubitemid 38145531)
7. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21:309-18. (Pubitemid 29157789)
8. Jeyakumar A, Younis T. Trastuzumab for HER2-positive metastatic breast cancer: clinical and economic considerations. ClinMed Insights Oncol 2012;6:179-87.
9. Smyth EC, Cunningham D. Targeted therapy for gastric cancer. Curr Treat Options Oncol 2012;13:377-89.
10. Yip AY, Tse LA, Ong EY, Chow LW. Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review. Anticancer Drugs 2010;21:487-93.
11. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006;8:215.
12. WongAL, Lee SC. Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int J Breast Cancer 2012;2012:415170.
13. Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, et al. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res 2011;71:7080-90.
14. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-6. (Pubitemid 38523885)
15. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69:9330-6.
16. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30.
17. Blackwell KL, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 30, 2012 (suppl; abstr LBA1).
18. Oude Munnink TH, Dijkers EC, Netters SJ, Lub-de Hooge MN, Brouwers AH, Haasjes JG, et al. Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. J Clin Oncol 2010;28:e355-6.
19. Uil TG, Haisma HJ, Rots MG. Therapeutic modulation of endogenous gene function by agents with designed DNA-sequence specificities. Nucleic Acids Res 2003;31:6064-78. (Pubitemid 37442334)
20. Sera T. Zinc-finger-based artificial transcription factors and their applications. Adv Drug Deliv Rev 2009;61:513-26.
21. Huisman C, Wisman GB, Kazemier HG, van Vugt MA, van der Zee AG, Schuuring E, et al. Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by artificial transcription factors. Mol Oncol 2013;7:669-79.
22. Lara H, Wang Y, Beltran AS, Juarez-Moreno K, Yuan X, Kato S, et al. Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J Biol Chem 2012;287:29873-86.
23. van der Gun BT, Huisman C, Stolzenburg S, Kazemier HG, RuitersMH, Blancafort P, et al. Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer. Br J Cancer 2013;108:881-6.
24. Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res 2012;40:6725-40.
25. Lund CV, Popkov M, Magnenat L, Barbas CF III. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology. Mol Cell Biol 2005;25: 9082-91. (Pubitemid 41429096)
26. Beerli RR, Dreier B, Barbas CF III. Positive and negative regulation of endogenous genes by designed transcription factors. Proc Natl Acad Sci U S A 2000;97:1495-500. (Pubitemid 30118469)
27. de Groote ML, Verschure PJ, Rots MG. Epigenetic editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes. Nucleic Acids Res, 2012;40:10596-613.
28. Rivenbark AG, Stolzenburg S, Beltran AS, Yuan X, Rots MG, Strahl BD, et al. Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics 2012;7:350-60.
29. Siddique AN, Nunna S, Rajavelu A, Zhang Y, Jurkowska RZ, Reinhardt R, et al. Targeted methylation and gene silencing of VEGF-A in human cells by using a designed Dnmt3a-Dnmt3L single-chain fusion protein with increased DNA methylation activity. J Mol Biol 2013;425:479-91.
30. Snowden AW, Gregory PD, Case CC, Pabo CO. Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Curr Biol 2002;12:2159-66. (Pubitemid 36021896)
31. Beerli RR, Segal DJ, Dreier B, Barbas CF III. Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks. Proc Natl Acad Sci U S A 1998;95:14628-33. (Pubitemid 29003681)
32. Esteve PO, Patnaik D, Chin HG, Benner J, Teitell MA, Pradhan S. Functional analysis of the N- and C-terminus of mammalian G9a histone H3 methyltransferase. Nucleic Acids Res 2005;33:3211-23. (Pubitemid 41194465)
33. van der Gun BT, de Groote ML, Kazemier HG, Arendzen AJ, Terpstra P, Ruiters MH, et al. Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancer. Br J Cancer 2011;105:312-9.
34. Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettner R, et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ERnegative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010;31:512-20.
35. Mishra SK, Mandal M, Mazumdar A, Kumar R. Dynamic chromatin remodeling on the HER2 promoter in human breast cancer cells. FEBS Lett 2001;507:88-94. (Pubitemid 33000303)
36. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, et al. Histone deacetylase inhibitor LAQ824 downregulates her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2003;2:971-84.
37. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010;28:1069-78.
38. Federico M, Bagella L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol 2011;2011:475641.
39. Yu Y, Zeng P, Xiong J, Liu Z, Berger SL, Merlino G. Epigenetic drugs can stimulate metastasis through enhanced expression of the prometastatic ezrin gene. PLoS ONE 2010;5:e12710.
40. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M,Coleman B, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011;1:598-607.
41. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapyresistant breast cancer. Br J Cancer 2011;104:1828-35.
42. Juarez-Moreno K, Erices R, Beltran AS, Stolzenburg S, Cuello-Fredes M, Owen GI, et al. Breaking through an epigenetic wall: re-activation of OCT4 by KRAB-containing designer zinc finger transcription factors. Epigenetics 2013;8:164-76.
43. Quenneville S, Turelli P, Bojkowska K, Raclot C, Offner S, Kapopoulou A, et al. The KRAB-ZFP/KAP1 system contributes to the early embryonic establishment of site-specific DNA methylation patterns maintained during development. Cell Rep 2012;2: 766-73.
44. Groner AC, Tschopp P, Challet L, Dietrich JE, Verp S, Offner S, et al. The kruppel-associated box repressor domain can induce reversible heterochromatization of a mouse locus in vivo. J Biol Chem 2012; 287:25361-9.
45. Peters AH, Kubicek S, Mechtler K, O'Sullivan RJ, Derijck AA, Perez- Burgos L, et al. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Mol Cell 2003;12:1577-89. (Pubitemid 38037024)
46. Lund CV, Blancafort P, Popkov M, Barbas CF III. Promoter-targeted phage display selections with preassembled synthetic zinc finger libraries for endogenous gene regulation. J Mol Biol 2004;340: 599-613. (Pubitemid 38798003)
47. Visser AE, Verschure PJ, Gommans WM, Haisma HJ, Rots MG. Step into the groove: engineered transcription factors as modulators of gene expression. Adv Genet 2006;56:131-61. (Pubitemid 43776134)
48. Hurst HC. Update on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res 2001;3:395-8. (Pubitemid 34196367)